Legend

Presentation Icons

CME

Non-CME

In Person

On Demand

Live Stream

Active Learning

Choose Rheum

Emerging Investigator Awardee

Poster Session

Periodic Fever Syndromes, Autoinflammatory Diseases, Still’s Disease and MAS/HLH

Poster Session A

Session: (0233–0279) Miscellaneous Rheumatic & Inflammatory Diseases Poster I

0263: A Multicenter Retrospective Case Series of Patients with Susac Syndrome Treated with Rituximab

Sunday, October 26, 2025

10:30 AM - 12:30 PM Central Time

Location: Hall F1

Abstract Poster Presenter(s)

MB

Michelle Benjamin, MD

Stanford Health Care
Palo Alto, California, United States

Disclosure(s): No financial relationships with ineligible companies to disclose

Background/Purpose: Susac Syndrome (SuS) is a rare immune-mediated vasculo-occlusive disease characterized by a triad of encephalopathy, hearing loss, and branched retinal artery occlusions. Deficits can be permanent and there is limited data to guide treatment. Here, we describe the treatment trajectories of a series of patients with SuS treated with rituximab.

Methods: A retrospective chart review of patients with SuS treated with rituximab and followed in neurology and/or rheumatology clinics at three tertiary care centers in the United States was performed.

Results: Eight patients -- 4 (50%) females, 7 (87.5%) with the complete SuS triad, median age of 47 years (range 21-66 years) -- were included. There were 11 instances of rituximab treatment (1 patient received 3 distinct courses) -- 8 (72.7%) for ≥ 6 months (3 are ongoing) and 3 (27.3%) for < 6 months. Co-treatment with prednisone occurred in 10 (90.9%) instances -- all 7 instances of rituximab ≥ 6 months reached steroid freedom; all 3 instances of rituximab < 6 months saw a decrease in daily prednisone dose by ≥ 30mg, but none reached steroid freedom. Mycophenolate mofetil (MMF) co-treated patients continued at the same dose, decreased, and weaned off MMF completely over 4 (36.4%), 2 (18.2%), 4 (36.4%) instances of rituximab treatment respectively. In the 4 (36.4%) rituximab instances involving co-treatment with intravenous immunoglobulin G (IVIg), the total monthly IVIg dose was decreased over 2 (50.0%) rituximab instances and weaned off completely over 1 (25.0%) instance. Additional co-treatments included methotrexate and azathioprine in 1 instance each, both of which were weaned off completely during rituximab treatment. No patients were co-treated with cyclophosphamide (though 1 was treated cyclophosphamide before rituximab initiation).

Conclusion: In this case series of patients with SuS, rituximab facilitated steroid freedom and tapering of other immunotherapeutic agents. These initial findings provide evidence supporting the use of rituximab in SuS.